Webcast ImageWebcast
Q1 2016 Laboratory Corporation of America Holdings Earnings Conference Call (Replay)
04/25/16 at 9:00 a.m. ET
Corporate Profile

Laboratory Corporation of America® Holdings, an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services through LabCorp Diagnostics, and end-to-end drug development support through Covance Drug Development. LabCorp is a pioneer in commercializing new diagnostic technologies and is improving people’s health by delivering the combination of world-class diagnostics, drug development and knowledge services. With combined revenue pro... More >>

Recent NewsMore >>
04/25/16Laboratory Corporation of America® Holdings Announces 2016 First Quarter Results and Raises 2016 Guidance
Q1 Net revenue of $2.3 billion, up 30% over last year Q1 Diluted EPS of $1.55; Q1 Adjusted EPS of $2.02, up 15% over last year 2016 Adjusted EPS guidance raised to $8.55 – $8.95, up 8% to 13% over 2015 BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 25, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced results for the quarter ended March 31, 2016. “We... 
Printer Friendly Version
04/11/16LabCorp Hires Jonathan Zung as Group President of Clinical Development and Commercialization Services for Covance Drug Development
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 11, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced that Jonathan Zung, Ph.D., has been named group president, Clinical Development & Commercialization Services for Covance Drug Development, effective April 5, 2016. Zung joins LabCorp from UCB, where he was vice president and head of Global Clinical Sciences and Operations, with responsibility for clinical operations, ... 
Printer Friendly Version
04/04/16Conversion Right Triggered for Labcorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 4, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
03/21/16LabCorp Completes Acquisition of Assets of Pathology, Inc.
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 21, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) has completed the previously-announced acquisition of substantially all of the operating assets of Pathology, Inc. following the satisfaction of all closing conditions. The acquisition includes Pathology, Inc.’s patient service centers used to conduct its medical testing and services business. “The added capabilities of Path... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
LH (Common)
Change Stock is Down 0.25
Intraday High$125.74
Intraday Low$124.32
Data as of 04/29/16
4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Reports & Performance

2014 Annual Report

2013 Annual Report

2012 Annual Report

2011 Annual Report

2010 Annual Report

2009 Annual Report

2008 Annual Report

2007 Annual Report

2006 Annual Report

Latest Earnings Release